DOCSLIB.ORG

IMMUNOPHENOTYPING of LYMPHOCYTES in HEALTHY and IMMUNODEFICIENT CHILDREN Vries, Esther De

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IMMUNOPHENOTYPING of LYMPHOCYTES in HEALTHY and IMMUNODEFICIENT CHILDREN Vries, Esther De IMMUNOPHENOTYPING OF LYMPHOCYTES IN HEALTHY AND IMMUNODEFICIENT CHILDREN Vries, Esther de Immunophenotyping of lymphocytes in healthy and immunodeficient children I Esther de Vries. - Rotterdam: Erasmus Universiteit Rotterdam, Afdeling Immunologie. - ill. Proefschrift Rotterdam. - Met lit. opg. ISBN 90-73436-47-8 Trefwoorden: Immunofenotypering, immunodeficientie, Iymfocyten, kinderen. Key words: Immunophenotyping, immunodeficiency, lymphocytes, children. No part of this thesis may be reproduced or transmitted in any form by any means, electronic or mechanical, including photocopying, recording or IMMUNOLOGIE any information storage and retrieval system, ROTTERDAM without permission in writing from the publisher (Department of Immunology, E. de Vries, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands). IMMUNOPHENOTYPING OF LYMPHOCYTES IN HEALTHY AND IMMUNODEFICIENT CHILDREN IMMUNOFENOTYPERING BIJ GEZONDE KINDEREN EN KINDEREN MET EEN AFWEERSTOORNIS PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr. P.W.C. Akkermans MA en volgens besluit van het College voor Promoties. De open bare verdediging zal plaatsvinden op woensdag 28 april 1999 om 15.45 uur door Esther de Vries geboren te Amsterdam. PROMOTIECOMMISSIE: Promotoren: Prof. dr. J.J.M. van Dongen Prof. dr. J.M.J.J. Vossen Overige leden: Prof. dr. R. de Groot Prof. dr. R. Benner Prof. dr. H.J. Neijens Dr. M.J.D. van Tol Het uitgeven van dit proefschrift werd mede mogelijk gemaakt door: Abbott B.V., Amgen BV., Boehringer Ingelheim BV., Glaxo Wellcome BV., Merck Sharp & Dohme B.V., Pfizer B.V., Astra Pharmaceutica BV., Friesland Nutrition en Alk Benelux BV. Omslagontwerp: Sascha Jansz, 10 jaar. Dit proefschrift werd bewerkt binnen de vakgroep Immunologie van de Faculteit der Geneeskunde en Gezondheidswetenschappen, Erasmus Universiteit Rotterdam/Academisch Ziekenhuis Rotterdam, de vakgroep Kindergeneeskunde van de Faculteit der Geneeskunde, Leids Universitair Medisch Centrum, en de vakgroep Kindergeneeskunde van het Sophia Kinderziekenhuis/Academisch Ziekenhuis Rotterdam. Het proefschrift werd gedrukt door Haveka B.V. te Alblasserdam. A/s schepen e/kaar mel unverfroren vader/andsliefde de grond inboren van de indonesische archipel a/s raketten sneller dan hel ge/uid afgevuurd aile kanlen uit ons ruimschools voorzien van kippevel is er moed voor nodig om ler wereld Ie komen - maar zie, de zon schijnl door de bomen en de meisjes hebben zich mooi gemaakt. is hel geen heer/ijke dag vandaag? de feeen om je wieg zullen goed voor je zorgen E s I her - wees welkom. Goedemorgen! januari 1962 Wim Wi/mink Aan mijn ouders, Arjan, Sascha en Robin 7 IMMUNOPHENOTYPING OF LYMPHOCYTES IN HEALTHY AND IMMUNODEFICIENT CHILDREN CONTENTS PART I Technical aspects of immunophenotyping in children Chapter 1: Introduction 11 Chapter 2: Flow cytometric immunophenotyping of lymphocytes 17 Chapter 3: Correction for erythroid cell contamination in 25 microassay for immunophenotyping of neonatal lymphocytes Arch Dis Child, 1999, in press PART II Lymphocyte subpopulatlons in healthy children Chapter 4: Analyzing the developing lymphocyte system of neonates 37 and infants Eur J Pediatr, 1999, in press Chapter 5: Neonatal blood lymphocyte subpopulations: 51 a different perspective when using absolute counts Submitted Chapter 6: Longitudinal follow-up of blood lymphocyte subpopulations 65 from birth to one year of age J Pediatr 1998;133:586-588 Chapter 7: Longitudinal survey of lymphocyte subpopulations in the 71 first year of life Submitted 8 PART III Lymphocyte subpopulations in Immunodeficient children Chapter 8: Immunophenotyping in the diagnosis and 95 follow-up of immunodeficient children Submitted Chapter 9: Reconstitution of lymphocyte subpopulations after 109 pediatric bone marrow transplantation Submitted Chapter 10: Identification of an unusual FcyReceptor Ilia (CD16) on 127 natural killer cells in a patient with recurrent infections Blood 1996;88:3022-3027 Chapter 11: TCRall+ T-Iymphocytopenia in two siblings 139 Submitted Chapter 12: The 782C-n (T254M) XHIM mutation: lack of a tight 147 phenotype-genotype relationship Submitted Chapter 13: A girl with agammaglobulinemia and absent blood 153 B-Iymphocytes PART IV Discussion and summary Chapter 14: General discussion 163 Summary 171 Samenvatting 177 Dankwoord 179 Curriculum vitae 183 PART I TECHNICAL ASPECTS OF IMMUNOPHENOTYPING IN CHILDREN I I I I I I I I 11 CHAPTER 1 INTRODUCTION 13 INTRODUCTION This thesis describes the use of immunophenotyping of lymphocytes in healthy as well as immunodeficient children. Part I describes the applied techniques (Chapters 2 and 3). The experimental work in healthy children is described in Part II (Chapters 4-7) and Part III describes the experimental work in immunodeficient children (Chapters 8-13). A summary and discussion of the work is given in Part IV. Chapter 2 shortly describes some technical aspects of flow cytometric immunophenotyping of lymphocytes. The advantages of using the lysed whole blood technique with directly conjugated monoclonal antibodies are discussed. In Chapter 3 a microassay for immunophenotyping of neonatal and infant lymphocytes is described. This microassay was developed for the study of healthy children during their first year of life, to enable detailed immunophenotyping in a small volume of blood (0.5 to 1.0 ml). In neonatal cord blood samples, contamination of the flow cytometric "Iympho-gate" wHh erythroid cells leads to underestimation of lymphocyte subpopulations. This erythroid contamination can be easily identified with the GpNCD71/CD45 triple immunostaining, which allows correction for the presence of erythroid cells wHhin the "Iympho-gate". Chapter 4 constitutes the introduction to the immunophenotyping stUdies in healthy children. Problems and pHfalis encountered in the study of the developing pediatric lymphocyte system are discussed, and literature data on the current knowledge of lymphocyte development in neonates and infants are summarized. The age-related differences in lymphocyte subpopulations and function imply that the available adult reference values cannot be used in children. In Chapter 5 the actual sizes (Le. the absolute counts) of the "naive" and "mature" blood lymphocyte subpopulations are compared between preterm neonates, term neonates, and adults. Unexpectedly, "mature" blood lymphocyte subpopulations appeared to be present in comparable absolute counts in term neonates and adults. However, "naive" lymphocyte subsets occurred in essentially higher absolute counts in term neonates, suggesting that a large pool of "naive" (untriggered) cells is standby in neonates, ready for partiCipation in primary immune responses. This pool of "naive" lymphocytes was not so large in some preterm neonates, which may partly explain their higher susceptibility to infections. Chapter 6 presents the longitudinal follow-up study of T-Iymphocytes, 8- lymphocytes, and NK-cells in ten healthy children from birth to one year of age. T­ and B-Iymphocytes increased at one and six weeks of age, respectively, whereas NK-cells showed a sharp decline directly after birth. These data show that the changes in size of the lymphocyte subpopulations that are found in cross-sectional studies are confirmed in longitudinal studies of individual children. 14 CHAPTER 1 In Chapter 7 the longitudinal follow-up of several subpopulations of T­ lymphocytes, B-Iymphocytes, and NK-cells during the first year of life is shown. Unexpectedly, the CD45RO+ T -lymphocyte count did not change during the first year of life, whereas the CD45RA+ T -lymphocyte count increased markedly, providing a large pool of cells for participation in primary immune responses. CD38 (T- and B-Iymphocytes) and CD1c and CD5 (B-Iymphocytes) are discussed as possible markers of peripheral immaturity. Finally, NK-cell subpopulations and their possible role before and after birth are discussed. Chapter 8 gives an introduction to the immunophenotyping studies in immunodeficient children. A stepwise protocol for the diagnosiS of immunodeficiency is presented, including an immunophenotyping protocol for clinical use. The role and interpretation of immunophenotyping results in the diagnostic process are discussed. In Chapter 9 the use of immunophenotyping in studying the slow reconstitution of lymphocyte subpopulations after pediatric bone marrow transplantation is illustrated. Especially the CD4+ helper T-Iymphocytes recovered slowly and reached the p, of age-matched reference values at a late stage (> 6 months posttransplant). The unexpected acceleration of the reconstitution of CD4+ helper T -lymphocytes in patients with CMV-reactivation is discussed. The posttransplant development of the absolute counts of CD45RA+, CD45RO+, and CD7- T­ lymphocyte counts are discussed in relation to normal ontogeny and the possibility of peripheral expansion of previously primed donor-derived "memory" T­ lymphocytes versus newly processed T-Iymphocytes via T-Iymphopoiesis in the thymus. In Chapter 10 the use of immunophenotyping is described for the identification of an unusual F,yReceptor lila (CD16) on NK-cells in a patient with recurrent infections. Loss of the epitope for the CD16 (B73.1) monoclonal antibody led to the identification of F,yRIIIA-48H/H homozygosity. The combined use of CD16 and CD56 monoclonal antibodies labeled with the same fluorescent dye, as is often applied in routine immunophenotyping procedures, will leave these
Load more

Recommended publications
  • Digitalcommons@UNMC Agranulocytosis
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1935 Agranulocytosis Gordon A. Gunn University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Gunn, Gordon A., "Agranulocytosis" (1935). MD Theses. 386. https://digitalcommons.unmc.edu/mdtheses/386 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. AGRANULOOYTOSIS ,- Senior Thesis by GOrdon .M.. Gunn INTRODUCTION Fifteen years ago the medioal profession new nothing of the disease spoken of in this paper as agranulocytosis. Since Schultz, in 1922, gave an accurate description of a fulminat­ ing case, agranulocytosis has oomettoClOCo.'UPy more and more prominence in the medical field. Today, the literature is fairly teeming with accounts of isolated cases of all descriptions. Added to this a confus­ ing nomenclature, varied classifications, and heterogeneous forms of treatment; and the large question of whether it is a disease entity, a group of diseases, or only a symptom complex, and some idea may be garnered as to the progress made. Time is a most important factor in diagnosis of this disease, and the prognosis at best is grave. The treatment has gone through the maze of trials as that of any other new disease; there must be a cause and so there must be some specific treatment.
    [Show full text]
  • Molecules with Specificity for Cd45 and Cd79 Moleküle Mit Cd45- Und Cd79-Spezifizität Molécules Présentant Une Spécificité Vis-À-Vis De Cd45 Et Cd79
    (19) *EP003169704B1* (11) EP 3 169 704 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) 29.07.2020 Bulletin 2020/31 (86) International application number: (21) Application number: 15738655.8 PCT/EP2015/066368 (22) Date of filing: 16.07.2015 (87) International publication number: WO 2016/009029 (21.01.2016 Gazette 2016/03) (54) MOLECULES WITH SPECIFICITY FOR CD45 AND CD79 MOLEKÜLE MIT CD45- UND CD79-SPEZIFIZITÄT MOLÉCULES PRÉSENTANT UNE SPÉCIFICITÉ VIS-À-VIS DE CD45 ET CD79 (84) Designated Contracting States: • WRIGHT, Michael John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Slough GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Berkshire SL1 3WE (GB) PL PT RO RS SE SI SK SM TR • TYSON, Kerry Designated Extension States: Slough BA ME Berkshire SL1 3WE (GB) Designated Validation States: MA (74) Representative: UCB Intellectual Property c/o UCB Celltech (30) Priority: 16.07.2014 GB 201412659 IP Department 208 Bath Road (43) Date of publication of application: Slough, Berkshire SL1 3WE (GB) 24.05.2017 Bulletin 2017/21 (56) References cited: (73) Proprietor: UCB Biopharma SRL WO-A1-2011/025904 WO-A1-2013/085893 1070 Brussels (BE) • GOLD ET AL.: "The B Cell Antigen Receptor (72) Inventors: Activates the AKT/Glycogegn Synthase Kinase-3 • FINNEY, Helene Margaret Signalling Pathway via Phosphatydilinositol Slough 3-Kinase", J. IMMUNOLOGY, vol. 163, 1999, Berkshire SL1 3WE (GB) pages 1894-1905, XP002745175, • RAPECKI, Stephen Edward Slough Berkshire SL1 3WE (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Leukocyte Adhesion Deficiency-I
    Clinical Communications Leukocyte adhesion deficiency-I: A this article’s Online Repository at www.jaci-inpractice.org for a comprehensive review of all published comprehensive listing of publications and patient numbers by cases country and Table E2 for a comprehensive listing of references). Elena Almarza Novoa, PhDa,b,*, Per investigator assessment, 113 patients were considered to have severe LAD-I, 63 moderate, and 147 not classified. Sanchali Kasbekar, PharmDc,*, d e Neutrophil CD18 expression was reported for 265 cases and was Adrian J. Thrasher, MD, PhD , Donald B. Kohn, MD , less than 2% in 135 patients (51%) and 2% or more in 130 Julian Sevilla, MD, PhDf, Tony Nguyen, MBAg, patients (49%). Four patients with CD18 greater than or equal Jonathan D. Schwartz, MDc,z, and to 2% were considered to have severe LAD-I (CD18% range, Juan A. Bueren, PhDa,b,z 2.4-17.3). Sex information was available for 282 patients, of which 148 (52%) were males. Clinical Implications Age at presentation was reported for 146 cases. For 63 patients with CD18 less than 2%, median presentation was at age 1 Leukocyte adhesion deficiency-I (LAD-I) is a rare, serious month (range, 0.03-18 months); for 62 patients with CD18 of disorder with severity determined by defective CD18 2% or more, median presentation was at age 6 months (range, expression. LAD-I is characterized by umbilical 0.03-192 months). HSCT was performed for 125 patients; 198 complications, granulocytosis, and diverse infections. patients did not undergo HSCT. Severe LAD-I is frequently fatal before the age of 2 years Infections were described for 248 (77%) of the 323 cases; fi without allogeneic transplant.
    [Show full text]
  • Khan CV 9-4-20
    CURRICULUM VITAE DAVID A. KHAN, MD University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas, TX 75390-8859 (214) 648-5659 (work) (214) 648-9102 (fax) [email protected] EDUCATION 1980 -1984 University of Illinois, Champaign IL; B.S. in Chemistry, Magna Cum Laude 1984 -1988 University of Illinois School of Medicine, Chicago IL; M.D. 1988 -1991 Good Samaritan Medical Center, Phoenix AZ; Internal Medicine internship & residency 1991-1994 Mayo Clinic, Rochester MN; Allergy & Immunology fellowship PROFESSIONAL EXPERIENCE 1994 -2001 Assistant Professor of Internal Medicine, UT Southwestern 1997 -1998 Co-Director, Allergy & Immunology Training Program 1998 - Director, Allergy & Immunology Training Program 2002- 2008 Associate Professor of Internal Medicine, UT Southwestern 2008-present Professor of Medicine, UT Southwestern AWARDS/HONORS 1993 Allen & Hanburys Respiratory Institute Allergy Fellowship Award 1993 Von Pirquet Award 2001 Outstanding Teacher 2000-2001 UTSW Class of 2003 2004 Outstanding Teacher 2003-2004 UTSW Class of 2006 2005 Outstanding Teacher 2004-2005 UTSW Class of 2007 2006 Daniel Goodman Lectureship, ACAAI meeting 2007 Most Entertaining Teacher 2006-2007 UTSW Class of 2009 2008 Stanislaus Jaros Lectureship, ACAAI meeting 2009 Outstanding Teacher 2007-2008 UTSW Class of 2010 2011 John L. McGovern Lectureship, ACAAI meeting 2012 I. Leonard Bernstein Lecture, ACAAI meeting 2014 Distinguished Fellow, ACAAI meeting 2015 Elliot F. Ellis Memorial Lectureship, AAAAI meeting 2015 Bernard Berman Lectureship,
    [Show full text]
  • • Cytosis: O Neutrophilia: Defined As an Increase in the Neutrophilic Count in the Peripheral Blood Above Reference Range for Age
    HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS-UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD NONNEOPLASTIC DISEASES OF THE WHITE BLOOD CELLS • There are five major types of WBCs in the blood: neutrophils, lymphocytes, eosinophils, basophils and monocytes. • The normal function of the white blood cells depends on a tight regulation of their count and their function. Therefore, disease develops if there is a derangement of the cells count or function, it takes one of the following forms: o Cytosis: increase in the number of circulating cells above reference range. (Note: leukocytosis means an increase in the WBC count, neutrophilia means increase in the neutrophilic count, lymphocytosis means increase in the lymphocytic count, monocytosis means increase in the monocytic count, basophilia means increase in the basophilic count and eosinophilia means in crease in the eosinophilic count). o Cytopenia: decrease in the number of circulating cells below reference range. (Note: neutropenia means decreased neutrophils, lymphocytopenia, or simply lymphopenia, means decrease in lymphocytes, monocytopenia means decrease in monocytes, eosinopenia means decrease in eosinophils, and basopenia means decrease in basophils). o Abnormal or absent function • Cytosis: o Neutrophilia: defined as an increase in the neutrophilic count in the peripheral blood above reference range for age. o Causes: bacterial infection is the most common and most important etiology. Tissue necrosis in cases of burns or trauma and medications such as epinephrine and corticosteroids are also additional causes for neutrophilia. § Some physiologic conditions can lead to neutrophilia such as stress, smoking and pregnancy. o Pathophysiology: neutrophils are present in the blood in two populations: circulating and marginal (meaning neutrophils stuck to the vessel wall).
    [Show full text]
  • Newborn Screening for Severe Combined Immunodeficiency And
    Newborn screening for SCID and related forms of Primary Immunodeficiency Michael Keller, MD Division of Allergy and Immunology Aims To review the epidemiology and possible presentations of primary immunodeficiency disorders. To learn about the TREC newborn screening assay, and what to do with a positive result. Speaker Disclosures No disclosures to declare. Case: 10 month old girl Ex FT infant, poor weight and chronic diarrhea since 2 months of age. No prior known infections, negative FH. Initial workup CBC: CMP: Na: 135 WBC: 5.6 K: 3.9 Hb: 11.3 Cl: 104 Hct: 34.1 CO2: 24 MCV: 79.1 BUN: 4 Plt: 386 Cr: 0.2 ANC: 2055 Glu: 70 Total protein: 4.9 ALC: 3102 Albumin: 3.0 Eos: 0.2% Alk Phos: 126 Monos: 6.9% ALT: 84 AST: 87 Phos: 4.8 Mg: 2.3 GGT: 17 Differential . Primary GI disease . IBD, allergic enterocolitis, . GI channelopathy . Metabolic disorder or CF . Newborn screening catches many but not all . Chronic infection . HIV . Immune disorder Further testing • Stool testing: negative for norovirus, enterovirus, parechovirus, adenovirus, O&P, culture • Negative CMV, EBV PCRs (blood) • Normal fecal elastase (434) • Positive Rotavirus Antigen EIA Further testing Hypogammaglobulinemia No vaccine responses Further testing Lymphocyte Flow Cytometry Marker Value Normal range (cells/mcl) (cells/mcl) CD3+ (T-cells) 242 1600-6700 CD3/CD4+ 86 1000-4600 CD3/CD8+ 15 400-2100 CD4/CD45RA+ 61 500-1100 CD4/CD45RO+ 57 150-600 CD16/56+, CD3- (NK cells) 223 200-1200 CD19+ (B-cells) 1735 600-2700 Profound T-cell Lymphocytopenia Diagnosis Dx: Severe combined immunodeficiency Epidemiology: Primary immunodeficiency Over 200+ known congenital immunologic defects • In total, primary immunodeficiency is thought to occur as frequent as 1 in 5000.
    [Show full text]
  • B Cell Checkpoints in Autoimmune Rheumatic Diseases
    REVIEWS B cell checkpoints in autoimmune rheumatic diseases Samuel J. S. Rubin1,2,3, Michelle S. Bloom1,2,3 and William H. Robinson1,2,3* Abstract | B cells have important functions in the pathogenesis of autoimmune diseases, including autoimmune rheumatic diseases. In addition to producing autoantibodies, B cells contribute to autoimmunity by serving as professional antigen- presenting cells (APCs), producing cytokines, and through additional mechanisms. B cell activation and effector functions are regulated by immune checkpoints, including both activating and inhibitory checkpoint receptors that contribute to the regulation of B cell tolerance, activation, antigen presentation, T cell help, class switching, antibody production and cytokine production. The various activating checkpoint receptors include B cell activating receptors that engage with cognate receptors on T cells or other cells, as well as Toll-like receptors that can provide dual stimulation to B cells via co- engagement with the B cell receptor. Furthermore, various inhibitory checkpoint receptors, including B cell inhibitory receptors, have important functions in regulating B cell development, activation and effector functions. Therapeutically targeting B cell checkpoints represents a promising strategy for the treatment of a variety of autoimmune rheumatic diseases. Antibody- dependent B cells are multifunctional lymphocytes that contribute that serve as precursors to and thereby give rise to acti- cell- mediated cytotoxicity to the pathogenesis of autoimmune diseases
    [Show full text]
  • Advances in Dental Research
    Advances in Dental Research http://adr.sagepub.com/ The Association Between Immunodeficiency and the Development of Autoimmune Disease J.W. Sleasman ADR 1996 10: 57 DOI: 10.1177/08959374960100011101 The online version of this article can be found at: http://adr.sagepub.com/content/10/1/57 Published by: http://www.sagepublications.com On behalf of: International and American Associations for Dental Research Additional services and information for Advances in Dental Research can be found at: Email Alerts: http://adr.sagepub.com/cgi/alerts Subscriptions: http://adr.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Downloaded from adr.sagepub.com by guest on July 18, 2011 For personal use only. No other uses without permission. THE ASSOCIATION BETWEEN IMMUNODEFICIENCY AND THE DEVELOPMENT OF AUTOIMMUNE DISEASE J.W. SLEASMAN aradoxically, individuals with primary or acquired immunodeficiency disease have an increased Division of Pediatric Immunology and Allergy incidence of autoimmunity. Human primary University of Florida College of Medicine immunodeficiency disease can be classified as Box 100296, 1600 SW Archer Road P disorders of cell-mediated immunity, humoral immunity, Gainesville, Florida 32610-0296 phagocytic cell function, and the complement system (Barrett and Sleasman, 1990). Cell-mediated and humoral immunity Adv Dent Res 10(l):57-61, April, 1996 comprise the adaptive arm of the immune response, which is antigen-specific and confers immunologic memory. The innate immune response, which is antigen-nonspecific, is Abstract—There is a paradoxical relationship between composed of phagocytic cells and the inflammatory peptides. immunodeficiency diseases and autoimmunity. While not all Not all individuals with inherited immunodeficiency develop individuals with immunodeficiency develop autoimmunity, autoimmunity, nor are all individuals with autoimmune nor are all individuals with autoimmunity immunodeficient, disease immunodeficient.
    [Show full text]
  • Molecular Design, Optimization and Genomic Integration of Chimeric B
    bioRxiv preprint doi: https://doi.org/10.1101/516369; this version posted June 5, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 Molecular design, optimization and genomic integration of chimeric B cell 2 receptors in murine B cells 3 4 Theresa Pesch1, Lucia Bonati1, William Kelton1, Cristina Parola1,2, Roy A Ehling1, Lucia 5 Csepregi1, Daisuke Kitamura3, Sai T ReDDy1,* 6 7 1 Department of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland 8 2 Life Science Graduate School, Systems Biology, ETH Zürich, University of Zurich, Zurich 8057, 9 Switzerland 10 3 Research Institute for Biomedical Sciences, Tokyo University of Science, Noda, Japan 11 *To whom corresponDence shoulD be aDDresseD. Tel: +41 61 387 33 68; Email: [email protected] 12 Key worDs: B cells, synthetic antigen receptor, cellular engineering, genome eDiting, cellular 13 immunotherapy, CRISPR-Cas9 14 15 Abstract 16 Immune cell therapies baseD on the integration of synthetic antigen receptors proviDe 17 a powerful strategy for the treatment of Diverse Diseases, most notably retargeting 18 T cells engineereD to express chimeric antigen receptors (CAR) for cancer therapy. In 19 aDDition to T lymphocytes, B lymphocytes may also represent valuable immune cells 20 that can be engineereD for therapeutic purposes such as protein replacement therapy 21 or recombinant antiboDy proDuction. In this article, we report a promising concept for 22 the molecular Design, optimization anD genomic integration of a novel class of 23 synthetic antigen receptors, chimeric B cell receptors (CBCR).
    [Show full text]
  • Cd79b Expression in B Cell Chronic Lymphocytic Leukemia: Its Implication for Minimal Residual Disease Detection
    Leukemia (1999) 13, 1501–1505 1999 Stockton Press All rights reserved 0887-6924/99 $15.00 http://www.stockton-press.co.uk/leu CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection JA Garcia Vela, I Delgado, L Benito, MC Monteserin, L Garcia Alonso, N Somolinos, MA Andreu and F On˜a Department of Hematology, Hospital Universitario de Getafe, Madrid, Spain The surface expression of CD79b, using the monoclonal anti- antigen expression and antigen overexpression) in order to body (Mab) CB3–1, on B lymphocytes from normal individuals establish the applicability of immunophenotypic aberrances and patients with B cell chronic lymphocytic leukemia (CLL) for monitoring MRD as in acute leukemias with a sensitivity has been analyzed using triple-staining cells for flow cytome- −4 try. In addition, the clinical significance of CD79b expression level of 10 (one aberrant CLL cell among 10000 normal in CLL patients and its possible value for the evaluation of mini- cells). We have previously published that CD5 is overex- mal residual disease (MRD) was explored. A total of 15 periph- pressed in most CLL cases.2 This aberrantly CD5high/CD19+ eral blood (PB) samples from healthy blood donors, five bone expression was present in 90% of our CLL. Dilutional experi- marrow (BM) samples from normal donors and 40 PB samples ments showed that CD5high/CD19+ were identified at fre- from CLL untreated patients were included in the study. In −4 addition we studied the expression of CD79b in B lymphocytes quencies as low as 10 . from five CLL patients after fludarabine treatment in order to Recently, different groups have communicated that CD79b support our method.
    [Show full text]
  • Digitalcommons@UNMC Granulocytopenia
    University of Nebraska Medical Center DigitalCommons@UNMC MD Theses Special Collections 5-1-1936 Granulocytopenia Howard E. Mitchell University of Nebraska Medical Center This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research. Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses Part of the Medical Education Commons Recommended Citation Mitchell, Howard E., "Granulocytopenia" (1936). MD Theses. 457. https://digitalcommons.unmc.edu/mdtheses/457 This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. G PA~lULOCYTOPENI A SENIOR THESIS By Howard E. Mitchell April 17, 1936 TABLE OF CONT'ENTS Introduction Definition • · 1 History . • • • 1 Nomenclature • • • • • 4 ClassificBtion • • • • 6 Physiology • • • • .10 Etiology • • 22 Geographic Distribution • 23 Age, Sex, and R9ce • • ·• 23 Occupation • .. • • • • .. • 23 Ba.cteria • • • • .. 24 Glandu18.r Dysfunction • • • 27 Radiation • • • • 28 Allergy • • • 28 Chemotactic and Maturation Factors • • 28 Chemicals • • • • • 30 Pathology • • • • • 36 Symptoms • • • • • • • 43 DiEtgnosis • • • • • .. • • • • • .. • 4'7 Prognosis 48 '" • • • • • • • • • • • • Treatment • • • • • • • • 49 Non"'specific Therapy • • • • .. 50 Transfusion • • • • .. 51 X-Ray • • • • • • • • • 52 Liver ·Extract • • • • • • • 53 Nucleotides • • • • • • • • • • • 53 General Ca.re • • • • • • • • 57 Conclusion • • • • • • • • • 58 480805 INTHODUCTION Although t~ere is reference in literature of the Nineteenth Century to syndromes similating the disease (granulocytopenia) 9.8 W(~ know it todes, it "vas not un­ til the year 1922 that Schultz 8ctually described his C8se as a disease entity and by so doing, stimulated the interest of tne medical profession to further in­ vestigation.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]